Gilead Sciences, Inc.

Gilead Pharmasset LLC

Nathan D Shapiro

Jeromy J Cottell

Zheng-Yu Yang

Darryl Kato

Scott D Schroeder

Elbert Chin

John O Link

James G Taylor

Elizabeth M Bacon

Michael L Mitchell

Teresa Alejandra Trejo Martin

Ashley Anne Katana

Nathan E Wright

Jiayao Li

Chienhung Chou

Qiaoyin Wu

Chao-I Hung

Hyung-Jung Pyun

Lan Jiang

Dustin S Siegel

Jennifer R Zhang

Hong Yang

Sheila M Zipfel

Gediminas J Brizgys

Hongyan Guo

Ana Zurisadai Gonzalez Buenrostro

Hang Chu

Rhiannon Thomas-Tran

Xiaochun Han

Suzanne M Szewczyk

Devleena M Shivakumar

James S Cassidy

Kavoos Kolahdouzan

Michael Graupe

Adam James Schrier

Michael Sangi

Ruben Martinez

Bruce Ross

Stephen E Ammann

Kapil Kumar Karki

Jonathan Clive Tripp

Gregg M Schwarzwalder

Katie Ann Keaton

Andrew W Waltman

Denise A Colby

Troy Evan Reynolds

Dominika Pcion

Johann Chan

Daniel G Shore

Lina Chan

Donald Tang

Adam Littke

Lawrence Yu

Pamela Seng

Chris Levins

Amy Cagulada

Richard L Mackman

Kevin S Currie

Winston C Tse

Eda Y Canales

Hon Chung Hui

Samuel E Metobo

Michael R Mish

Hai Yang

Gregory F Chin

Mark J Bartlett

Roland D Saito

David W Lin

Evangelos Aktoudianakis

Yunfeng Eric Hu

Michael O Clarke

Bindu Goyal

Jennifer Leigh Cosman

Doris T Tang

Ezra Roberts

Deeba Ensan

Megan K Armstrong

Stephen Ho

Gregg M Schwarzwälder

Sudha Kondapally

Sudha Kondappally

Jonathan Tripp

Ana Z Gonzalez Buenrostro

Troy Reynolds

The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.

GLP-1R modulating compounds

The invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a mammal using compounds of Formula I.

HIV inhibitor compounds

Compounds for use in treating or preventing human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R, R, L, W, W, X, Y, and Z are as defined herein. Methods associated with the preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use

The present disclosure provides pyrimidine dione compounds of Formula I

CD73 compounds

The invention provides a compound of Formula I:

The invention provides compounds having Formula (I): or a pharmaceutically acceptable salt thereof, as well as pharmaceutical compositions comprising the same, processes for their preparation, and methods of treating and preventing HIV infection by their administration.

Anti-HIV compounds

The present disclosure generally relates to compounds and pharmaceutical compositions which may be used in methods of treating a hepatitis B virus infection.

Compounds for the treatment of hepatitis B virus infection

Growing community of inventors

Belmont, CA, United States of America

Nathan D Shapiro